Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
16.70
+1.77 (11.86%)
Apr 1, 2026, 4:00 PM EDT - Market closed

Avalo Therapeutics Revenue

In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%. Avalo Therapeutics had revenue of $59.00K in the quarter ending December 31, 2025, a decrease of -69.27%.

Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
6,450.29
Revenue / Employee
$1,788
Employees
33
Market Cap
380.57M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202559.00K-382.00K-86.62%
Dec 31, 2024441.00K-1.48M-77.08%
Dec 31, 20231.92M-16.13M-89.34%
Dec 31, 202218.05M12.65M234.40%
Dec 31, 20215.40M-1.30M-19.42%
Dec 31, 20206.70M-51.35K-0.76%
Dec 31, 20196.75M-278.03K-3.96%
Dec 31, 20187.03M-20.78M-74.73%
Dec 31, 201727.81M26.66M2,312.27%
Dec 31, 20161.15M--
Dec 31, 2015---
Dec 31, 2014---
Dec 31, 2013---
Dec 31, 201282.76K--